<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">100962781</journal-id>
<journal-id journal-id-type="pubmed-jr-id">22270</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Rev Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Rev. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Nature reviews. Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1471-003X</issn>
<issn pub-type="epub">1471-0048</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30054570</article-id>
<article-id pub-id-type="pmc">6148363</article-id>
<article-id pub-id-type="doi">10.1038/s41583-018-0039-7</article-id>
<article-id pub-id-type="manuscript">NIHMS987614</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fenster</surname>
<given-names>Robert J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lebois</surname>
<given-names>Lauren A. M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ressler</surname>
<given-names>Kerry J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suh</surname>
<given-names>Junghyup</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Division of Depression and Anxiety Disorders, McLean Hospital Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.</aff>
<aff id="A2"><label>2</label>These authors contributed equally: Robert J. Fenster, Lauren A. M. Lebois.</aff>
<author-notes>
<fn fn-type="other" id="FN1">
<p id="P1">Author contributions</p>
<p id="P2">R.J.F., L.A.M.L., K.J.R. and J.S. researched data for the article, made substantial contributions to discussions of the conÂ­ tent, wrote the article and reviewed and/or edited the manuscript before submission.</p>
</fn>
<corresp id="CR1"><label>*</label><email>kressler@mclean.harvard.edu</email>; <email>jsuh@mclean.harvard.edu</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P51">Competing interests</p>
<p id="P52">K.J.R. is on the scientific advisory boards for Resilience Therapeutics, the Sheppard Pratt-Lieber Research Institute, the Laureate Institute for Brain Research, the Army Study to Assess Risk and Resilience in Servicemembers (STARRS) project, the University of California-San Diego VA Center of Excellence for Stress and Mental Health (CESAMH) and the Anxiety and Depression Association of America; provides fee-for-service consultation for Biogen and Resilience Therapeutics; and holds patents for the use of d-cycloserine and psychotherapy, targeting the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor for extinction, targeting tachykinin 2 for prevention of fear and targeting angiotensin to improve extinction of fear. R.J.F., L.A.M.L. and J.S. declare no competing interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>4</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>19</volume>
<issue>9</issue>
<fpage>535</fpage>
<lpage>551</lpage>
<!--elocation-id from pubmed: 10.1038/s41583-018-0039-7-->
<abstract id="ABS1">
<p id="P3">Post-traumatic stress disorder (PTSD) is a prevalent, debilitating and sometimes deadly consequence of exposure to severe psychological trauma. Although effective treatments exist for some individuals, they are limited. New approaches to intervention, treatment and prevention are therefore much needed. In the past few years, the field has rapidly developed a greater understanding of the dysfunctional brain circuits underlying PTSD, a shift in understanding that has been made possible by technological revolutions that have allowed the observation and perturbation of the macrocircuits and microcircuits thought to underlie PTSD-related symptoms. These advances have allowed us to gain a more translational knowledge of PTSD, have provided further insights into the mechanisms of risk and resilience and offer promising avenues for therapeutic discovery.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>